Kainos Medicine, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 10, 2027The maintenance fee for Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment (US 10,500,224) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme (US 9,271,969) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 29 US 12,746,271 Fas-Associated Factor 1 (FAF1)-Loaded Exosomes and Use Thereof as Anti-Cancer Agent
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,939,550 | Aminopyrazole Derivatives, Process for the Preparation Thereof, and Composition for Preventing or Treating Ischemic Diseases Containing the Same In force · High confidence | In force | High confidence | |
| US 9,271,969 | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme In force · USPTO record | In force | USPTO record | |
| US 10,500,224 | Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment In force · USPTO record | In force | USPTO record | |
| US 9,884,874 | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer In force · USPTO record | In force | USPTO record | |
| US 11,242,321 | Salt forms of organic compound In force · USPTO record | In force | USPTO record | |
| US 12,521,371 | Modulators of Alpha-Synuclein In force · High confidence | In force | High confidence | |
| US 12,534,452 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE Compound and Pharmaceutical Composition Comprising the Same as Active Ingredient In force · High confidence | In force | High confidence | |
| US 12,746,271 | Fas-Associated Factor 1 (FAF1)-Loaded Exosomes and Use Thereof as Anti-Cancer Agent In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 1 no status recorded